BioVie Inc.
BIVIW
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.48M
Close$
Share Statistics
| Market cap | $10.48 Million |
|---|---|
| Enterprise Value | $1.78 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 0.3 |
| Outstanding Shares | - |
Return
| Return on Equity | -215.34% |
|---|---|
| Return on Assets | -155.20% |
| Return on Invested Capital | -213.28% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioVie Inc
3 employees
CEO: Cuong Viet Do BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity i...